Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 3:10:1827-1857.
doi: 10.2147/CMAR.S166912. eCollection 2018.

Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists

James Gilmore  1 , Steven D'Amato  2 , Niesha Griffith  3 , Lee Schwartzberg  4   5
Affiliations
Review

Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists

James Gilmore et al. Cancer Manag Res. .

Abstract

Purpose: To discuss new therapeutic strategies for chemotherapy-induced nausea and vomiting (CINV) involving 5-hydroxytryptamine type 3 (5HT3)-receptor antagonists (RAs).

Summary: CINV remains poorly controlled in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC); nausea and delayed-phase CINV (24-120 hours after chemotherapy) are the most difficult to control. National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) antiemesis-guideline recommendations for HEC include a four-drug regimen (5HT3 RA, neurokinin 1 [NK1] RA, dexamethasone, and olanzapine). For some MEC regimens, a three-drug regimen (5HT3 RA, NK1 RA, and dexamethasone) is recommended. While 5HT3 RAs have dramatically improved CINV in the acute phase (0-24 hours after chemotherapy), their efficacy declines in the delayed phase. Newer formulations have been developed to extend 5HT3-RA efficacy into the delayed phase. Granisetron extended-release subcutaneous (GERSC), the most recently approved 5HT3 RA, provides slow, controlled release of therapeutic granisetron concentrations for ≥5 days. GERSC is included in the NCCN and ASCO guidelines for MEC and HEC, with NCCN-preferred status for MEC in the absence of an NK1 RA. Efficacy and safety of 5HT3 RAs in the context of guideline-recommended antiemetic therapy are reviewed.

Conclusion: Recent updates in antiemetic guidelines and the development of newer antiemet-ics should help mitigate CINV, this dreaded side effect of chemotherapy. GERSC, the most recently approved 5HT3-RA formulation, is indicated for use with other antiemetics to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of MEC and anthracycline-cyclophosphamide combination-chemotherapy regimens.

Keywords: chemotherapy-induced nausea and vomiting; granisetron; granisetron extended-release injection; granisetron extended-release subcutaneous; serotonin-receptor antagonist.

PubMed Disclaimer

Conflict of interest statement

Disclosure JG has served as a member of a speaker bureau or advisory committee for Heron Therapeutics. LS has acted in a consultant/advisory role for Eisai, Helsinn, Merck, and Tesaro, received research funding from Helsinn, and served as a member of a speaker bureau or advisory committee for Helsinn and Merck. NG has served as a member of a speaker bureau or advisory committee for Eisai, Heron, and Tesaro. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Extended-release formulations of granisetron: plasma granisetron concentrations following administration. Notes: Data from these studies.–, Dashed line indicates minimum therapeutic concentration of granisetron 2 ng/mL (data from patent application 20120258164 for granisetron transdermal delivery system).
Figure 2
Figure 2
Biochronomer technology mechanism of action.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472–4478. - PubMed
    1. Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013;73(3):249–262. - PubMed
    1. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5):497–503. - PubMed
    1. Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer. 2011;19(6):843–851. - PubMed
    1. van Laar ES, Desai JM, Jatoi A. Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. Support Care Cancer. 2015;23(1):151–157. - PMC - PubMed

LinkOut - more resources